China's Next Round Of Drug Price Cuts? NDRC To Slash Prices On More Products On National Drug Reimbursement List
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's New Drug Price Guidelines are expected to be released by the end of this year, which are likely to lead to another round of price cuts on drugs included on the National Drug Reimbursement List, according to analysts
You may also be interested in...
China Sets New Rule For Drug Price Differentiation
China’s National Development and Reform Commission Dec. 2 releases new regulation on drug price differentiation intended to close loopholes.
Lost Patent Protection? Move To China, Says Specialty Biotech SciClone
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company
Lost Patent Protection? Move To China, Says Specialty Biotech SciClone
The value of brand in China has helped SciClone consistently grow sales of its branded flagship product Zadaxin even with no IP protection and significant generic competition. Indicated for hepatitis B and hepatitis C, Zadaxin has generated $80 million in sales in China and is the backbone of the small biotech company